Layn(SZ:002166) Mei Ri Jing Ji Xin Wen·2025-11-04 13:15Core Viewpoint - The company, Rhein Biotech, faced a production safety accident on August 21, 2025, resulting in a fine of 600,000 yuan and recommendations for accountability for several management personnel [1][2][3]. Incident Details - The accident was caused by an operator's failure to follow operational procedures, leading to a flash explosion that resulted in one death and multiple injuries [2][3]. - The estimated property damage from the incident is over 2 million yuan [2]. Company Response - The company is accelerating the update and reconstruction of the affected drying workshop, with plans to resume operations by early 2026 [1]. - External experts have been invited to assess safety risks and develop corrective measures, which will be supervised by government authorities [1][4]. Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.272 billion yuan, an increase of 8.73% year-on-year, but a net profit of 70.4 million yuan, a decrease of 30.73% [4][5]. - The third quarter saw a revenue decline of 2.09% and a net profit decrease of 12.10% compared to the previous year [5]. - The company attributes the decline in profit margins to tariffs and depreciation of new production capacity, but expects improvement in the fourth quarter due to seasonal demand and operational efficiency [5][6]. Cash Flow and Business Development - The net cash flow from operating activities for the first three quarters reached 346 million yuan, a significant increase of 142.73% year-on-year [6]. - The company is focusing on customized services and product combinations to drive growth in its core natural sweetener business, with recent FDA GRAS certification for a new product [6].